Company / Financials
Sarepta Therapeutics Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$2.2B
FY2025 · +15.6% YoY
Net Income
-$713.4M
FY2025 · -403.3% YoY
Profit Margin
-32.5%
FY2025 · net income / revenue
ROE
-62.5%
FY2025 · return on equity
Total Assets
$3.3B
FY2025
Total Debt
$140.5M
0.12x debt/equity
Equity
$1.1B
FY2025
ROA
-21.3%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$2.2B+15.6% YoYNet Income HistoryProfit after all expenses and taxes-$713.4M-403.3% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$25.5MOperating Income HistoryProfit from core business operations before interest and taxes-$699.8M-420.9% YoYSG&A Expense HistorySelling, general, and administrative expenses$491.7M-11.9% YoYR&D Expense HistoryResearch and development spending$1.5B+89.2% YoYInterest Expense HistoryCost of borrowing and debt obligations$1.9M+110.3% YoYIncome Tax HistoryTotal income tax expense$11.2M-56.2% YoYEPS (Basic) HistoryBasic earnings per share-$5.80+27.8% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$5.80+27.8% YoY